For further processing only. Others UDP-Galactose animal-free UDP-Galactose animal-free 78 1403506419168 The sale of the Product does not exhaust or grant any rights in third party patents including patents of companies of the F. Hoffmann - La Roche AG group of companies, in particular, for the use of modified antibodies obtained by using the product. 3.2.17.2.3.3 disodium salt, lyophilizate 07703562103 UDP-Galactose animal-free UDP-Galactose animal-free 07613336133316 Reagents, kits custom fill Not Available Unit of measure is "gram". Benefits of using in vitro glycoengineering to modify glycosylation of therapeutic proteins: Time- and cost-saving generation of glycan variants to develop improved drugs Optimized glycosylation without compromising other CQAs or product yield Improved lot-to-lot consistency to reduce risk of product quality variation and resulting delays Generation of glycoprofiles which may not otherwise be generated Streamlined analytics in comparability studies en UDP-Galactose animal-free is an activated sugar, and can be used for in vitro glycoengineering of glycoproteins, e.g. therapeutic proteins. en UDP-Galactose animal-free is a disodium salt, provided as a white, lyophilized substance. en Incubation of UDP-Galactose and β-1,4-Galactosyltransferase with a glycoprotein leads to increased galactosylation of the glycoprotein. en Appearance: White, lyophilized substanceSolution (c=100 mg/mL water): Clear, colorlesspH value: 5.0 - 7.0UDPgal.,di-Na (A260, ε= 9.9 [Lxmmol-1xcm-1]): ≥ 80.0%UDP-galactose (HPLC): ≥ 95.0 area%Na (flamefotom.): 6.0-8.0%Water (K.Fischer): ≤ 10.0%UDP (HPLC): ≤ 1.5 area%UMP (HPLC): ≤ 1 area%Uridine (HPLC): ≤ 0.5 area%UTP (HPLC): ≤ 0.2 area%Total unknown impurities (HPLC): ≤ 1 area%Heavy metals (as Pb): ≤ 25 ppmPinorg. ≤ 0.4 %Iron (AAS): ≤ 10 ppmBioburden: ≤ 100 CFU/gStability: At +2 to +8°C within specification range for 24 months. en